Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. (Q53347418)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. (English)

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

0 references

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

author name string

Felsenberg D

1

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

Alenfeld F

2

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

Bock O

3

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

Hammermeister C

4

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

Gowan W

5

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

publication date

1 November 1998

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

31

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

1

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

35-44

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

Osteoporosis. Frequency, consequences, and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidemiology of hip fractures: implications of the exponential increase with age.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hip fractures in the elderly: a world-wide projection

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term fracture prediction by bone mineral assessed at different skeletal sites

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-existing fractures and bone mass predict vertebral fracture incidence in women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2898%2900050-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0378-5122(98)00050-4

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

1 reference

Europe PubMed Central

13 May 2018

http://europepmc.org/abstract/MED/10091203

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53347418&oldid=1407811881"